Patents Expiring in October 2026
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actelion | UPTRAVI | selexipag | POWDER;INTRAVENOUS | 214275-001 | Jul 29, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG | ||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-001 | Dec 21, 2015 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG | ||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-002 | Dec 21, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG | ||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-003 | Dec 21, 2015 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG | ||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-004 | Dec 21, 2015 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |